Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
Símbolo de cotizaciónCDTTW
Nombre de la empresaConduit Pharmaceuticals Inc
Fecha de salida a bolsaFeb 03, 2022
Fundada en2021
Director ejecutivoDr. Andrew Regan
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección4851 Tamiami Trail North
CiudadNAPLES
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal34103
Teléfono16464919132
Sitio Webhttps://www.conduitpharma.com/
Símbolo de cotizaciónCDTTW
Fecha de salida a bolsaFeb 03, 2022
Fundada en2021
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos